Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
AssigneesInstitut Curie, Centre National De La Recherche Scientifique, Onxeo, Institut National de la Sante et de la Recherche Medicale, Universite Paris-Sud 11
InventorsMarie Dutreix, Wael Jdey
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
Claims26
A method of treating cancer comprising the administration of a pharmaceutical composition comprising a nucleic acid molecule and a Poly (ADP ribose) polymerase (PARP) inhibitor, wherein the nucleic acid molecule is a hairpin nucleic acid with a double-stranded DNA stem and a loop and has the following formula:
- wherein N is a deoxynucleotide, n is an integer from 23 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is 0 or 1, p is 1, and wherein the nucleic acid molecule has less than 70% sequence identity to any gene in a human genome to a subject having cancer.
A method of treating cancer comprising administering, to a subject having cancer, a PARP inhibitor in combination with a DBait nucleic acid molecule, wherein the DBait nucleic acid molecule is a hairpin nucleic acid with a double-stranded DNA stem and a loop and has the following formula:
- wherein N is a deoxynucleotide, n is an integer from 23 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is 0 or 1 p is 1, and wherein the DBait nucleic acid molecule has less than 70% sequence identity to any gene in a human genome.
A method of treating cancer comprising administering, to a subject having cancer, a DBait nucleic acid molecule in combination with a PARP inhibitor, wherein the DBait nucleic acid molecule is a hairpin nucleic acid with a double-stranded DNA stem and a loop and has the following formula:
- wherein N is a deoxynucleotide, n is an integer from 23 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is 0 or 1 p is 1, and wherein the DBait nucleic acid molecule has less than 70% sequence identity to any gene in a human genome.
Dependencies are inferred from the claim text.